Patient Disease:
Canine Splenic Hemangiosarcoma
Study Name:
SOCH (Scout Out Hemangiosarcoma) Study
Purpose of the study:
- To assess the safety and effectiveness of a specially designed vaccine for HSA when given with standard surgery and doxorubicin chemotherapy
Primary Eligibility Criteria:
- Confirmed diagnosis of hemangiosarcoma of the spleen having undergone splenectomy within 3 weeks prior to entry
- Adequate blood work
- No cardiac disease that would contraindicate doxorubicin administration
- No evidence of spread of disease beyond spleen
- Pets must come to CSU for all visits related to the clinical trial
Study Protocol:
- All dogs receive standard doxorubicin chemotherapy every 2 weeks for 5 treatments
- Dogs are randomized 1:1 to receive either the active vaccine or a placebo which is given every 4 weeks for up to 48 weeks
- Blood samples will be collected for study purposes every 4 weeks
- Restaging with chest x-rays and abdominal ultrasound is performed every 8 weeks
Owner Responsibilities:
- You are responsible for the costs of surgery to remove your dog’s spleen and any other tests recommended by your pet’s oncologist
- You are responsible for the costs of exam fees for the duration of the study and treatment of any side effects of doxorubicin
- You are expected to make and keep all appointments associated with the study
Financial Incentives:
- All other costs related to the study are covered, including tests to determine study eligibility, blood tests, chest x-rays and abdominal ultrasound, chemotherapy, and the cost of the vaccine
If you have further questions about any of our clinical trials, please submit an online consult form. Your consult will then be directed to our trials team. Requests are typically returned within 5 business days.